Login to Your Account

Efficacy Under Fire, Too

FDA Briefing Docs: Calcitonin Cancer Risk 'Appears Plausible'

By Jennifer Boggs
Managing Editor

Monday, March 4, 2013

Briefing documents released ahead of Tuesday's FDA advisory meeting to discuss the risk-benefit profile of calcitonin-containing drugs in osteoporosis said that the cancer risk associated with the polypeptide hormone "appears plausible" and "cannot be ignored," signaling another potential blow to the drug class, which has seen its share of the osteoporosis market decline over the past decade.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription